Heart failure is a leading cause of death worldwide, and patients with severe heart failure require left ventricular assist device (LVAD) support. LVAD is usually implanted as a bridge to transplantation (BTT) or destination but can be removed if the patient’s cardiac function recovers. We performed liquid chromatography–mass spectrometry on myocardial samples from heart transplant recipientHowever to identify the molecular predictors for cardiac prognosis after LVAD implantation. Ref: Shintani-Domoto Y, Ode KL, Nomura S et al. Circulation 152, 1518-1521 (2025)